Group 1 - The medical sector showed signs of recovery, with major player United Imaging Healthcare rising over 3%, while other stocks like WuXi AppTec and Aier Eye Hospital fell more than 1% [1] - The largest medical ETF in A-shares (512170) experienced a decline of over 2.8% in the morning but recovered slightly in the afternoon, ultimately dropping over 1%, marking a four-month low [1] - A-shares' three major indices collectively fell over 2% [1] Group 2 - The medical ETF (512170) fell below its six-month moving average and approached a critical yearly support level, with significant trading volume of over 874 million yuan, setting a new monthly high for daily trading [3] - In the first four trading days of the week, over 627 million yuan flowed into the ETF, indicating potential bottom-fishing activity despite the risk of larger sell-offs [3] - The medical ETF has a current scale exceeding 25.3 billion yuan, making it the largest medical-related ETF in the market, with a focus on "medical devices + medical services" [3][4] Group 3 - The ETF's composition includes a significant weighting of over 26% in CXO, along with leading companies in aesthetic medicine, private hospitals, and medical information technology [3] - The ETF is passively tracking the CSI Medical Index, which was established on December 31, 2004, and published on October 31, 2014 [4]

Summary of Key Points Core Viewpoint - The announcement details the shareholding situation and the results of a share reduction plan by major shareholders of Yisui Technology Group Co., Ltd. The shareholders, Tianjin Sequoia and Beijing Sequoia, have executed a plan to reduce their holdings through block trading. Group 1: Shareholding Situation - Before the reduction plan, Tianjin Sequoia held 11,785,883 shares (5.89% of total shares), and Beijing Sequoia held 5,547,286 shares (2.77% of total shares) [1] - The shares held by these shareholders were acquired before the company's IPO and through capital reserve conversion [1] Group 2: Reduction Plan Implementation Results - On July 24, 2025, the company disclosed a plan for Tianjin Sequoia and Beijing Sequoia to reduce their holdings by up to 4,004,367 shares (up to 2% of total shares) [1] - During the reduction period, Tianjin Sequoia and Beijing Sequoia reduced their holdings by a total of 3,002,184 shares, representing 1.42% of the current total shares [2] - The reduction plan was completed as scheduled, and the actual reduction met the planned minimum reduction quantity [7]

Market Overview - The Shanghai Composite Index closed at 3949.83 points, with a decline of 0.56% [1] - The total trading volume of A-shares reached 1,296.161 billion yuan [1] Technical Analysis - A total of 112 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Shanshui Bide (300844) with a distance of -1.40% - Yingboer (300681) with a distance of -1.28% - Yake Technology (002409) with a distance of -1.06% [1] Individual Stock Performance - Shanshui Bide (300844) saw a decline of 6.62% with a trading turnover rate of 3.31% [1] - Yingboer (300681) decreased by 2.30% with a turnover rate of 2.45% [1] - Yake Technology (002409) fell by 0.20% with a turnover rate of 2.33% [1] - Other notable declines include: - Bohai Automobile (600960) down by 3.53% - Western Gold (601069) down by 2.80% [1] Additional Stock Movements - Stocks such as Muyu (002714) and Qinglong (002457) showed slight increases of 0.80% and -3.28% respectively [2] - The stock performance of various companies indicates a mixed sentiment in the market, with several stocks experiencing declines while a few managed to gain [2]

Summary of Key Points Core Viewpoint - Several companies are experiencing significant shareholder reductions, indicating potential shifts in ownership and market sentiment towards these firms [1]. Shareholder Reductions - Huijie Co., Ltd. shareholder Lin Shengzhi plans to reduce holdings by up to 2% [1] - Goko Technology's major shareholder Beikong intends to reduce holdings by up to 0.7% [1] - Zhouming Technology's chairman Lin Mingfeng plans to reduce holdings by up to 1.99% [1] - Keheng Co., Ltd. shareholder Wang Guojiang plans to reduce holdings by up to 2% [1] - Fulian Precision's actual controller An Zhifu plans to reduce holdings by up to 1% [1] - Baoli Food's shareholder Shanghai Houxu plans to reduce holdings by up to 3% [1] - Huizhiwei's shareholder GZPA plans to reduce a total of up to 10.52 million shares [1] - Yijiahe's shareholder Zhejiang Junhong plans to reduce holdings by up to 2% [1] - Dexin Technology's shareholder Xinjiang Guotou plans to reduce holdings by up to 2.3351 million shares [1] - Yirui Technology's shareholders Tianjin Sequoia and Beijing Sequoia plan to reduce a total of 3.0022 million shares [1] - Boliview's shareholder Zhang Zhiping has completed a reduction of 2.3756 million shares [1] - Fubon Technology's Zhenghong Development plans to reduce holdings by up to 0.59% [1] - Liaoti Technology's shareholder Alibaba has reduced holdings by 4.2392 million shares [1] Regulatory Actions - Kexin Information is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [1] - *ST Xinyan's stock trading will be subject to additional delisting risk warnings [1]

（文章来源：证券日报） 证券日报网讯 11月17日晚间，奕瑞科技发布公告称，本次减持计划实施前，奕瑞电子科技集团股份有 限公司（以下简称"公司""奕瑞科技"）股东天津红杉聚业股权投资合伙企业（有限合伙）（以下简 称"天津红杉"）、北京红杉信远股权投资中心（有限合伙）（以下简称"北京红杉"）分别持有公司股份 11，785，883股和5，547，286股，分别占本次减持前公司总股本的5.89%和2.77%。近日，公司收到股 东天津红杉、北京红杉出具的《关于奕瑞科技大宗交易减持股份计划实施情况的告知函》，在减持计划 期间内，天津红杉、北京红杉通过大宗交易的方式减持公司股份合计3，002，184股，占公司当前股份 总数的1.42%。 ...

格隆汇11月17日丨奕瑞科技(688301.SH)公布,近日，公司收到股东天津红杉、北京红杉出具的《关于奕 瑞科技大宗交易减持股份计划实施情况的告知函》，在减持计划期间内，天津红杉、北京红杉通过大宗 交易的方式减持公司股份合计300.22万股，占公司当前股份总数的1.42%。 ...

Group 1 - The core point of the article is that Yirui Technology (SH 688301) announced a reduction in shareholding by major shareholders Tianjin Sequoia and Beijing Sequoia, with a total of approximately 3 million shares sold through block trading, accounting for 1.42% of the company's total shares [1] - As of the report, Yirui Technology has a market capitalization of 22 billion yuan [2] - For the fiscal year 2024, Yirui Technology's revenue composition is as follows: digital X-ray detectors account for 93.53%, while other businesses make up 6.47% [1]

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-098 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 关于股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 本次减持计划实施前，奕瑞电子科技集团股份有限公司（以下简称"公司" "奕瑞科技"）股东天津红杉聚业股权投资合伙企业（有限合伙）（以下简称"天 津红杉"）、北京红杉信远股权投资中心（有限合伙）（以下简称"北京红杉"）分 别持有公司股份 11,785,883 股和 5,547,286 股，分别占本次减持前公司总股本的 5.89%和 2.77%。上述股份均为公司 IPO 前及上市后权益分派资本公积转增股本 取得的股份，该部分股份已于 2021 年 9 月 22 日、2023 年 4 月 24 日、2024 年 6 月 17 日、2025 年 6 月 19 日上市流通。 减持计划的实施结果情况 2 ...

Core Viewpoint - The Medical Health Index (980016) closed at 6572.66 points, down 0.65%, with a trading volume of 23.397 billion yuan and a turnover rate of 0.87% on November 14 [1] Group 1: Index Performance - Among the index constituents, 16 stocks rose while 33 stocks fell, with Ganli Pharmaceutical leading the gainers at a 2.0% increase and Yirui Technology leading the decliners at a 3.74% decrease [1] - The top ten constituents of the Medical Health Index include major companies such as WuXi AppTec, Hengrui Medicine, and Mindray Medical, with respective weights of 13.66%, 11.00%, and 7.57% [1] Group 2: Market Capitalization and Stock Prices - The total market capitalization of the top ten constituents ranges from 553.09 billion yuan for Kelun Pharmaceutical to 4603.55 billion yuan for Rihai Shenzhou, with stock prices varying from 12.25 yuan to 298.80 yuan [1] - The performance of the top ten stocks shows a mix of slight declines, with WuXi AppTec down 1.49% and Hengrui Medicine down 1.04% [1] Group 3: Capital Flow - The Medical Health Index constituents experienced a net outflow of 472 million yuan from major funds, while retail investors saw a net inflow of 388 million yuan [1] - Detailed capital flow data indicates that Ganli Pharmaceutical had a net inflow of 62.98 million yuan from major funds, despite a net outflow from retail investors [2]

| 证券代码：688301 | 证券简称：奕瑞科技 公告编号：2025-097 | | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | 奕瑞电子科技集团股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的 提示性公告 持股 5%以上股东天津红杉聚业股权投资合伙企业（有限合伙）及其一致行 动人北京红杉信远股权投资中心（有限合伙）保证向本公司提供的信息真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少 | ☑ | | --- | --- | --- | --- | --- | | 权益变动前合计比例 | 7.66% | | | | | 权益变动后合计比例 | 6.78% | | | | | 本次变动是否违反已作出的承诺、意向、 | 是□ | 否☑ | | | | 计划 | | | | | | 是否触发强制要约收购义务 | 是□ | 否☑ | | | | | □ | 控股股东/实控人 | | | --- | --- | --- | -- ...